Searched for
AJANTA PHARMA USFDA
USFDA issues Form-483 with 5 observations to Ajanta Pharma's Paithan facilityAjanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra...- Ajanta Pharma earmarks Rs 250 crore capex for current fiscal"During the current year (FY22), we are estimating the capex to be in the vicinity of Rs 250 crore. It will largely go towards maintenance ...
- Trending stocks: Ajanta Pharma shares rise 4.31%The stock quoted a 52-week high of Rs 1536.5 and a 52-week low of Rs 825.
- USFDA inspects Dahej facility, no observations issued: Ajanta PharmaOur formulation facility at Dahej was inspected by US FDA from July 23-27, 2018. At the end of the inspection, no Form 483 was issued to us...
- Lupin slumps to 4-year low as USFDA issues warning letter for Goa, Indore plantsThe warning letter was issued on Monday for Pithampur unit II of Indore and its Goa plant.
- Ajanta Pharma gets USFDA nod for Parkinson's disease tabletIn a BSE filing, Ajanta Pharma said it has recieved "final approval for Entacapone tablets from US FDA. It is a bioequivalent generic versi...
- USFDA completes inspection of Dahej unit: Ajanta PharmaForm 483 is issued to a company's management after completion of inspection of its facility to notify regarding objectionable conditions.
- Ajanta Pharma denies alert from USFDA, says supply is onThere has been media reports saying the company has got import alert from US FDA for its Paithan unit at Aurangabad.
- Ajanta Pharma slips over 14% on USFDA import alertAjanta Pharma was trading 4.35 per cent lower at Rs 1,706 in early trade around 10.30 am (IST) on BSE.
- Ajanta Pharma launches BP lowering tablets in USAjanta Pharma's Amlodipine + Olmesartan Medoxomil tablets are a generic version of Daiichi Sankyo Inc's Azor tablets
- Ajanta Pharma launches acid reflux drug in USThe approval from the United States Food and Drug Administration (USFDA) is for the capsules in the strengths of 20mg/1100 mg and 40 mg/110...
- USFDA nods to Indian drugs up 84% in 1 yearInterestingly, the growth came during the period when biggies like Sun Pharma and Dr Reddy's had reduced filings from their plants due to c...
- Ajanta Pharma surges 2% on USFDA nodThe company has launched the drug in two strengths of 5 mg and 10 mg tablets to address different level of treatment after the approval fro...
- Ajanta Pharma launches anti-dementia drug in USThe US Food and Drug Administration has so far granted final approvals for 10 abbreviated new drug applications and 2 tentative approvals.
- Ajanta Pharma gets USFDA nod for migraine pain relief drugAjanta Pharma has received final approval for its generic version of acute migraine pain relief drug Zolmitriptan tablets from the US healt...
- Ajanta Pharma shares jump nearly 4% on USFDA nod for drugThe stock went up 3.69 per cent to Rs 1,448.80 on BSE.
- Ajanta Pharma gets USFDA nod for migraine pain relief drugThe approval is for multiple strengths of 6.25mg and 12.5mg of the generic version of Janssen Pharmaceuticals' Axert tablets, Ajanta Pharma...
- Ajanta Pharma launches generic asthma treatment tablets in USAjanta Pharma has launched its generic Montelukast Sodium tablets used for treatment of asthma and seasonal allergies in the American marke...
- Ajanta Pharma launches generic asthma drug in US marketAjanta Pharma today said it has launched generic version of Singulair granules, used in the treatment of asthma, in the US market.
- Ajanta Pharma gets USFDA nod for generic asthma treatment drugDrug firm Ajanta Pharma has received final approvals from the US health regulator for generic montelukast tablets and oral granules.
Load More
